In recent years, we’ve seen the emergence of the second-generation anti-angiogenics as the gold standard for treating wet AMD. We’ve seen incredible success, I would say, one of the biggest successes ...

There are a variety of ways that I would like to see new technology used in wet AMD in the future.

The MarketWatch News Department was not involved in the creation of this content. Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class ...

Wet age-related macular degeneration (wet AMD) is a progressive eye disease in which abnormal, fragile blood vessels grow under the macula and leak fluid or blood, leading to irreversible central ...

Tolerability of VLTR-559 assessed at the anticipated clinical dose for less frequent dosing Positive safety results observed across multiple measures of eye health, including intraocular pressure and ...

4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all ...

New non-human primate (NHP) data for VLTR-559, a long-acting anti-VEGF therapy that could reduce the dosing frequency for the treatment of wet age-related macular degeneration (AMD) to twice-yearly, ...

MARINA Trial (2006) Ranibizumab is effective in wet AMD (minimal adverse effects) Randomized trial resulted in FDA approval of ranibizumab, the current first-line treatment for wet AMD ANCHOR Trial ...

Concerns arise as Medisep 2 excludes essential eye treatment for age-related macular degeneration, risking vision for Kerala’s pensioners.

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...